Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

479.50 -3.78 (-0.78%)
Streaming Delayed Price Updated: 10:42 AM EDT, Jun 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 149,792
Open 481.82
Bid (Size) 479.36 (1)
Ask (Size) 479.70 (2)
Prev. Close 483.28
Today's Range 478.38 - 482.23
52wk Range 335.82 - 486.43
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets

Performance

YTD
+16.69%
+16.69%
1 Month
+11.53%
+11.53%
3 Month
+15.69%
+15.69%
6 Month
+34.58%
+34.58%
1 Year
+37.33%
+37.33%

More News

Read More
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Via Benzinga
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
This Is What Whales Are Betting On Vertex Pharmaceuticals
Via Benzinga
3 No-Brainer Stocks to Buy in June
Via The Motley Fool
5 Top Stocks to Buy in June
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
Via Chartmill
2 Biotech Stocks to Buy in May
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
Via Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Via Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Via The Motley Fool
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Via Benzinga
Got $500? 3 Pharma Stocks to Buy and Hold Forever
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.